200 related articles for article (PubMed ID: 23940785)
1. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
Li Z; Qiu Y; Personett D; Huang P; Edenfield B; Katz J; Babusis D; Tang Y; Shirely MA; Moghaddam MF; Copland JA; Tun HW
PLoS One; 2013; 8(8):e71754. PubMed ID: 23940785
[TBL] [Abstract][Full Text] [Related]
2. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Tun HW; Johnston PB; DeAngelis LM; Atherton PJ; Pederson LD; Koenig PA; Reeder CB; Omuro AMP; Schiff D; O'Neill B; Pulido J; Jaeckle KA; Grommes C; Witzig TE
Blood; 2018 Nov; 132(21):2240-2248. PubMed ID: 30262659
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide Reduces Ischemic Brain Injury in Rodents.
Tsai YR; Tweedie D; Navas-Enamorado I; Scerba MT; Chang CF; Lai JH; Wu JC; Chen YH; Kang SJ; Hoffer BJ; de Cabo R; Greig NH; Chiang YH; Chen KY
Cell Transplant; 2019 Apr; 28(4):439-450. PubMed ID: 31094216
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
[TBL] [Abstract][Full Text] [Related]
6. DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
Travers M; Brown SM; Dunworth M; Holbert CE; Wiehagen KR; Bachman KE; Foley JR; Stone ML; Baylin SB; Casero RA; Zahnow CA
Cancer Res; 2019 Jul; 79(13):3445-3454. PubMed ID: 31088836
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
8. Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer.
Rahal OM; Wolfe AR; Mandal PK; Larson R; Tin S; Jimenez C; Zhang D; Horton J; Reuben JM; McMurray JS; Woodward WA
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1034-1043. PubMed ID: 29485045
[TBL] [Abstract][Full Text] [Related]
9. Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival.
Barros MH; Segges P; Vera-Lozada G; Hassan R; Niedobitek G
PLoS One; 2015; 10(5):e0124531. PubMed ID: 25978381
[TBL] [Abstract][Full Text] [Related]
10. Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat.
Wang JY; Huang YN; Chiu CC; Tweedie D; Luo W; Pick CG; Chou SY; Luo Y; Hoffer BJ; Greig NH; Wang JY
J Neuroinflammation; 2016 Jun; 13(1):168. PubMed ID: 27353053
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Sehgal K; Das R; Zhang L; Verma R; Deng Y; Kocoglu M; Vasquez J; Koduru S; Ren Y; Wang M; Couto S; Breider M; Hansel D; Seropian S; Cooper D; Thakurta A; Yao X; Dhodapkar KM; Dhodapkar MV
Blood; 2015 Jun; 125(26):4042-51. PubMed ID: 25869284
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.
Bastea LI; Liou GY; Pandey V; Fleming AK; von Roemeling CA; Doeppler H; Li Z; Qiu Y; Edenfield B; Copland JA; Tun HW; Storz P
Cancer Res; 2019 Apr; 79(7):1535-1548. PubMed ID: 30696657
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
Houillier C; Choquet S; Touitou V; Martin-Duverneuil N; Navarro S; Mokhtari K; Soussain C; Hoang-Xuan K
Neurology; 2015 Jan; 84(3):325-6. PubMed ID: 25527263
[No Abstract] [Full Text] [Related]
14. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
Kadoch C; Dinca EB; Voicu R; Chen L; Nguyen D; Parikh S; Karrim J; Shuman MA; Lowell CA; Treseler PA; James CD; Rubenstein JL
Clin Cancer Res; 2009 Mar; 15(6):1989-97. PubMed ID: 19276270
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
Locatelli SL; Careddu G; Serio S; Consonni FM; Maeda A; Viswanadha S; Vakkalanka S; Castagna L; Santoro A; Allavena P; Sica A; Carlo-Stella C
Clin Cancer Res; 2019 Feb; 25(3):1098-1112. PubMed ID: 30352904
[TBL] [Abstract][Full Text] [Related]
17. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
Fudaba H; Momii Y; Hirakawa T; Onishi K; Asou D; Matsushita W; Kawasaki Y; Sugita K; Fujiki M
Sci Rep; 2021 Jan; 11(1):1206. PubMed ID: 33441719
[TBL] [Abstract][Full Text] [Related]
18. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma.
Komohara Y; Horlad H; Ohnishi K; Ohta K; Makino K; Hondo H; Yamanaka R; Kajiwara K; Saito T; Kuratsu J; Takeya M
J Clin Exp Hematop; 2011; 51(2):93-9. PubMed ID: 22104307
[TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
20. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
